Pfizer Inc. (PFE)
Pre-market:
| Previous close | 26.32 |
| Open | 26.25 |
| Bid | 26.22 x 3200 |
| Ask | 26.34 x 1300 |
| Day's range | 26.04 - 26.34 |
| 52-week range | 25.23 - 40.37 |
| Volume | |
| Avg. volume | 42,211,908 |
| Market cap | 148.755B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 71.00 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.68 (6.40%) |
| Ex-dividend date | 25 Jan 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 1-Ad group WPP reports 1.6% drop in first-quarter organic growth
British ad group WPP reported a 1.6% drop in organic growth in the first quarter, lagging its major rivals, after it was hit by loss of business from healthcare client Pfizer and reduced spending by technology companies. WPP, which had already warned that any organic growth this year would be weighted towards the second half, on Thursday reiterated its guidance for flat to 1% growth this year, with a margin improvement of 20-40 basis points.
- Investor's Business Daily
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?
- Zacks
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
